Advancing earlier insight.
Enabling deeper understanding.
Driving the future of cancer detection.
Investigational blood-based technologies supporting the future of early cancer screening.
The challenge
of late detection
Survival outcomes across many cancers remain strongly associated with stage at diagnosis
Many cancers are still diagnosed at advanced stages
OUR APPROACH
Scientific rigor.
Real-world focus.
Supported by ongoing clinical validation, our technology advances scalable, data-driven approaches investigating molecular signatures associated with early-stage disease.
Scientific collaboration
Working with leading experts
and the world’s best
cancer centers
Multi-omic technology
Integrating molecular signals
for the detection of
early cancer signs
Scaleable platform
Developed for
real-world
implementation
Clinical validation
Ongoing studies
across cohorts
and countries
Our mission
Wholomics is developing next-generation liquid biopsy technologies aimed at advancing early cancer detection and clinical impact.
Through a simple blood draw, our approach supports minimally invasive strategies for earlier insight into disease.
>>We are dedicated to shaping a future where earlier detection can create more opportunities for intervention and care <<
Our Organization
Learn more about our work in novel minimally invasive liquid biopsy technologies focused on early cancer detection and precision oncology.
Take Action
Be part of the shift toward more data-driven and personalized approaches to cancer care.
Explore how you can contribute, collaborate, or engage with our work in next generation liquid-biopsy technologies.